Modalis Loss Widens on Higher R&D Spend Amid Zero Revenue in FY2025

Modalis Therapeutics Corporation ( (JP:4883) ) has shared an update.

Modalis Therapeutics has reported a widening loss for the fiscal year ended December 31, 2025, with consolidated operating income falling to a deficit of ¥2,211 million and profit attributable to owners of the parent deepening to a loss of ¥2,152 million. The company again posted no operating revenue, underscoring its status as a pre-commercial R&D-driven biotech.

On a non-consolidated basis, operating income deteriorated to a loss of ¥2,302 million and net profit to a loss of ¥2,249 million, though the per-share loss narrowed slightly to ¥29.11. Management attributed the larger losses across both consolidated and non-consolidated results to higher research and development expenses, highlighting an aggressive investment stance that could weigh on near-term earnings while aiming to support longer-term pipeline progress.

The most recent analyst rating on (JP:4883) stock is a Hold with a Yen60.00 price target. To see the full list of analyst forecasts on Modalis Therapeutics Corporation stock, see the JP:4883 Stock Forecast page.

More about Modalis Therapeutics Corporation

Modalis Therapeutics Corporation is a Tokyo Stock Exchange–listed biotechnology company focused on developing gene therapy and genetic medicine platforms. The company is positioned in the research and development stage, with spending concentrated on advancing its pipeline rather than generating operating revenue at this time.

Average Trading Volume: 837,280

Technical Sentiment Signal: Sell

Current Market Cap: Yen4.99B

See more insights into 4883 stock on TipRanks’ Stock Analysis page.